Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.

Literature DB >> 31154918

From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.

Deepa Rangachari¹, Daniel B Costa¹.

Abstract

Entities: Disease

Year: 2019 PMID： 31154918 PMCID： PMC6879313 DOI： 10.1200/JCO.19.01207

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

× No keyword cloud information.

22 in total

1. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

Authors: Deepa Rangachari; Xiuning Le; Meghan Shea; Mark S Huberman; Paul A VanderLaan; Susumu S Kobayashi; Daniel B Costa
Journal: J Thorac Oncol Date: 2017-06-10 Impact factor: 15.609

2. Cancer statistics, 2019.

Authors: Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal: CA Cancer J Clin Date: 2019-01-08 Impact factor: 508.702

3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors: Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal: Lancet Date: 2016-12-13 Impact factor: 79.321

4. Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors: Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors: Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal: Lancet Date: 2015-12-19 Impact factor: 79.321

6. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245

7. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors: Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245

8. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

9. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.

Authors: Jose M Pacheco; Dexiang Gao; Derek Smith; Thomas Purcell; Mark Hancock; Paul Bunn; Tyler Robin; Arthur Liu; Sana Karam; Laurie Gaspar; Brian Kavanagh; Chad Rusthoven; Dara Aisner; Robert Doebele; D Ross Camidge
Journal: J Thorac Oncol Date: 2018-12-30 Impact factor: 15.609

10. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors: Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal: N Engl J Med Date: 2018-06-04 Impact factor: 91.245

8 in total

1. The rapidly evolving landscape of biomarker testing in non-small cell lung cancer.

Authors: Paul A VanderLaan; Deepa Rangachari; Daniel B Costa
Journal: Cancer Cytopathol Date: 2020-08-05 Impact factor: 5.284

Review 2. Potential Role of Neutrophil Extracellular Traps in Cardio-Oncology.

Authors: Kai-Hung Cheng; Gregory P Contreras; Ting-Yu Yeh
Journal: Int J Mol Sci Date: 2022-03-25 Impact factor: 5.923

3. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.

Authors: Jia Chen; Sheng Wei; Tianye Zhao; Xunlei Zhang; Yilang Wang; Xiaodong Zhang
Journal: Dis Markers Date: 2022-07-30 Impact factor: 3.464

4. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy.

Authors: Deniz Can Guven; Taha Koray Sahin; Enes Erul; Ibrahim Yahya Cakir; Enes Ucgul; Hasan Cagri Yildirim; Oktay Halit Aktepe; Mustafa Erman; Saadettin Kilickap; Sercan Aksoy; Suayib Yalcin
Journal: J Clin Med Date: 2022-08-03 Impact factor: 4.964

5. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.

Authors: Xiaoling Shang; Wengang Zhang; Xun Zhang; Miao Yu; Jingwen Liu; Yufeng Cheng; Bo Cheng
Journal: Front Immunol Date: 2022-09-29 Impact factor: 8.786

6. Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer.

Authors: Xiaoqun Nie; Liliang Xia; Fang Gao; Lixia Liu; Yi Yang; Yingying Chen; Huangqi Duan; Yaxian Yao; Zhiwei Chen; Shun Lu; Ying Wang; Chen Yang
Journal: Front Mol Biosci Date: 2021-05-21

7. Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc.

Authors: Yu Zhong; Liting Yang; Fang Xiong; Yi He; Yanyan Tang; Lei Shi; Songqing Fan; Zheng Li; Shanshan Zhang; Zhaojian Gong; Can Guo; Qianjin Liao; Yujuan Zhou; Ming Zhou; Bo Xiang; Xiaoling Li; Yong Li; Zhaoyang Zeng; Guiyuan Li; Wei Xiong
Journal: Signal Transduct Target Ther Date: 2021-06-25

8. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.

Authors: Kartik Sehgal; Anushi Bulumulle; Heather Brody; Ritu R Gill; Shravanti Macherla; Aleksandra Qilleri; Danielle C McDonald; Cynthia R Cherry; Meghan Shea; Mark S Huberman; Paul A VanderLaan; Glen J Weiss; Paul R Walker; Daniel B Costa; Deepa Rangachari
Journal: Clin Lung Cancer Date: 2020-06-05 Impact factor: 4.785

8 in total